Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe. Motley Fool Transcribers ... Paul J. Arndt-- Investor Relations. 1 33. Albireo Pharma, Inc. 10 Post Office Square Suite 1000 Boston, MA 02109. Contact |  Terms of Use  |  Privacy Policy. Mac; iPad; iPhone; Watch; TV; Music; iTunes; HomePod La Società, la storia, i membri. Thank you, operator, and good morning, everyone. Tripadvisor, the world's largest travel platform*, helps 463 million travelers each month** make every trip their best trip. Investor Relations Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening … E-mail: invest@albemarle.com Albireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provides Business Update . Revenues came in … Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe. 2020© SALVATORE FERRAGAMO S.P.A. - P.IVA: 02175200480 Seguici su Wechat. The following slide deck was published by Albireo Pharma, Inc. in conjunction with this event. Thank you for joining today's call during which management will provide an update on Albireo… Source: Albireo Pharma, Inc. Albireo Pharma, Inc. Condensed Consolidated Balance Sheets The Investor Relations website contains information about Bentley Systems, Incorporated's business for stockholders, potential investors, and financial analysts. Meet the Albireo Pharma Board of Directors. Avanos Medical is a medical technology company focused on delivering clinically superior breakthrough medical device … The Investor Relations website contains information about Safilo Group S.p.A.'s business for stockholders, potential investors, and financial analysts. Investor Relations Global Contacts Albireo Pharma Inc ALBO Morningstar Rating Rating as of Nov 17, 2020. Informazioni Finanziarie. Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. Investor Relations Corporate Profile. 6 mo. VIEW ALL STOCK INFORMATION. Led by a management team with significant experience in … Minimum 15 minutes delayed. The Investor Relations website contains information about Addus HomeCare's business for stockholders, potential investors, and financial analysts. Meet the Albireo Pharma enterprise team. Minimum 15 minutes delayed. News Releases. Albireo Pharma (ALBO) Investor Presentation - Slideshow. Company Profile. Investor Relations Global Contacts ... -8263 (international), and provide the access code 13697430. CYBEROO nasce nel 2008 all’interno di un retaggio aziendale più ampio, consolidando l’odierno business nel 2019. BOSTON, Nov. 08, 2018 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced. -   Final PEDFIC 1 and interim PEDFIC 2 results   accepted   at AASLD’s The Liver Meeting 2020   - - PEDFIC   1 and   PEDFIC 2 : largest global Phase 3 in children with PFIC types 1,   2   &   3   - -   Two abstracts to be presented on new pipeline compound   - BOSTON , Nov. - Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases- - Scientific leadership demonstrate s c ompany’s   commitment to increase understanding of   rare pediatric cholestatic liver disease s and reduce burden   of illness - BOSTON , Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases BOSTON , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing, BOSTON , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’s common, Progressive Familial Intrahepatic Cholestasis (PFIC), Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome, Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC, New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease, Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences, Albireo Reports Q3 2020 Financial Results and Provides Business Update, Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers, Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting, Albireo Recognizes PFIC Awareness Day 2020. Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Contatti Investor Relations. The Investor Relations website contains information about Aeglea Biotherapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Data Provided by Refinitiv. Investors in Albireo Pharma, Inc. (NASDAQ:ALBO) had a good week, as its shares rose 4.1% to close at US$32.84 following the release of its quarterly results. Thank you for joining today's call. Investor Relations Events. Investor Relations Corporate Profile. David Chiswell, Ph.D. – Chairman Former CEO, Cambridge Antibody Technology (CAT), Nabriva Therapeutics and Kymab; Currently Chairman, Epsilogen and Board Member of Avillion Bond 2 Development 2 GP Legacy Housing Corporation is the fourth largest producer of manufactured homes in the United States and a recognized leader and innovator in the manufactured housing industry. Change Volume 52 Week High 52 Week Low Dec 19, 2020 9:08 AM EST. IREN è stata inclusa per la prima volta dal CDP nella "Climate Change A List" Il Gruppo è stato inserito tra le 8 aziende italiane virtuose nella lotta al cambiamento climatico: il comunicato stampa completo 1 yr. Data Provided by Refinitiv. Equal Opportunity Employer. read more. Find out more. Investor Relations Investor Relations Allakos is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. Operazioni di Cartolarizzazione. Medical Information (857) 378-2035 medinfo@albireopharma.com December 10, 2020 Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH. - Study represents Albireo’s third global, Phase 3 trial in rare cholestatic liver diseases -              - ASSERT gold standard study design in Alagille syndrome -   - Product submission of once-daily odevixibat for patients with PFIC under review by FDA and EMA - BOSTON , Dec. BOSTON , Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common, - Data   on PFIC types 1, 2, 3 submitted to support use across a wide range of patients - - EMA grants accelerated assessment , validates Marketing Authorization Application for odevixibat with o rphan d esignation and access to PRIority MEdicines (PRIME) - -   FDA has granted o devixibat   F ast T, - PEDFIC 1   meets   both U . This page shows the institutions and funds most likely to invest in ALBO / Albireo Pharma, Inc., based on analysis of their current holdings. 3 mo. Investor Relations Global Contacts GlobeNewswire Albireo Prices Public Offering of 4,000,000 Shares of Common Stock ... Sep 10, 2020 1:16 AM UTC. The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. ET — Shop and Learn. Albireo Pharma, Inc. (ALBO) Q3 2019 Earnings Call Transcript ALBO earnings call for the period ending September 30, 2019. A live audio webcast will be accessible from the Media & Investors page of Albireo… Investor Relations Investor Relations Corporate Profile. Albireo Pharma, Inc. is an equal opportunity employer and does not discriminate against any applicant because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, disability, genetic information, veteran status, military status, application for military service or any other class protected by state or federal law. III Pilastro. The Investor Relations website contains information about Laredo Petroleum, Inc.'s business for stockholders, potential investors, and financial analysts. Albireo, a biotechnology company, develops therapeutic drugs for gastrointestinal diseases. ET — Investor Relations Tripadvisor is the world's largest travel site. Investor Relations. Investor Relations. Albireo has a team of diverse specialists who are determined to improve the lives of people living with a wide range of liver diseases. 1 yr. Corporate Profile. Investor Relations Investor Relations Corporate Profile. ... Vice President of Investor Relations and … Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences Nov 12, 2020 Albireo Reports Q3 2020 Financial Results and Provides Business Update Albireo B, di magnitudine 5,1 è invece una stella di classe B8 di sequenza principale, quindi di colore bianco-azzurro, avente una temperatura superficiale di 12.100 kelvin, molto più elevata di quella solare; la sua massa è calcolata essere 3,3 volte quella solare.La sua luminosità è 190 volte quella solare. An archived version of the webcast will be available for replay on the Events & Presentations section of the Media & Investors page of Albireo’s website for 3 months following the event. Paul J. Arndt-- Investor Relations Thank you, operator, and good morning, everyone. Per la trasmissione e lo stoccaggio delle Informazioni Regolamentate, la Società si avvale del sistema di diffusione eMarket SDIR e del meccanismo di stoccaggio eMarket STORAGE disponibile all’indirizzo www.emarketstorage.com gestiti da Spafid Connect S.p.A., con sede in Foro Buonaparte 10, Milano. Albireo Energy has developed a world-class operating team of leaders with wide experience in the building automation, energy efficiency, fire and security contracting business. Corporate Development & Investor Relations Charlotte, NC, USA Phone: 980-299-5601 Mark de Boer Director Corporate Strategy & Investor Relations Amsterdam, The Netherlands Phone: 31 20 634 7060. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. Investor Relations Global Contacts Albireo Pharma Inc ALBO Morningstar Rating Rating as of Nov 17, 2020. Investor Relations Global Contacts Albireo Pharma Inc ALBO Morningstar Rating Rating as of Oct 15, 2020. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. Bilanci. Albireo Pharma, Inc. | 5,339 followers on LinkedIn. March 2, 2020 — Phase 3 odevixibat PFIC trial fully enrolled — — Initiating pivotal trials in biliary atresia first half of 2020 and Alagille syndrome by year end— — Management to host conference call and webcast today at 10:00 a.m. Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Albireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provides Business Update . Media Contact: Heather Anderson 6 Degrees 980-938-0260 handerson@6degreespr.com. Albireo Pharma, Inc. Common Stock (ALBO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Find the latest SEC Filings data for Albireo Pharma, Inc. Common Stock (ALBO) at Nasdaq.com. The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. Investor Relations Data Provided by Refinitiv. 6 mo. Quarterly Earnings Reports. In questa sezione sono pubblicati i documenti relativi a bilanci, III pilastro, rating, operazioni di cartolarizzazione. Relentlessly focused on liver disease | Albireo Pharma is a clinical-stage biopharmaceutical company focused through its … Jan Mattsson, Ph.D. Chief Scientific Officer, Managing Director (Sweden), and Co-Founder Albireo Pharma, Inc. ... Paul Arndt-- Investor Relations, LifeSci Advisors. Investor Contact: Hans Vitzthum LifeSci Advisors, LLC 212-915-2568. Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law. Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in … Explore SAP Investor Relations, with financial news, investor events, annual reports and quarterly statements and EU primary and secondary endpoints with high ly   statistically significant reductions in serum bile acids and pruritus   - - Interim results from long-term extension study   show sustained improvements in serum bile acids, pruritus - - Improvements in growth, BOSTON , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will present via webcast at the 2020 Jefferies London, -   P ositive P hase 3 d ata for   o devixibat in PFIC with filings on track for no later than early 202 1 - -   Phase 3 PFIC data accepted as late breakers at upcoming AASLD Meeting - - Introduces new and novel bile acid modulator A3907 at AASLD - -   Raised $160 million in gross proceeds in. S . Albireo Energy has developed a world-class operating team of leaders with wide experience in the building automation, energy efficiency, fire and security contracting business. Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Profile. The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. Investors MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. Paul J. Arndt-- Investor Relations Thank you, operator, and good morning, everyone. Minimum 15 minutes delayed. Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. Phone: (857) 254-5555. Investor Relations Founded in 2006 by Langley Steinert, co-founder of TripAdvisor, CarGurus is a global, online automotive marketplace connecting buyers and sellers of new and used cars. Investor Relations Overview. Home / Investors & Media / News Releases News Releases. Download PDF. Listen to webcast. March 2, 2020 — Phase 3 odevixibat PFIC trial fully enrolled — — Initiating pivotal trials in biliary atresia first half of 2020 and Alagille syndrome by year end— — Management to host conference call and webcast today at 10:00 a.m. Rating Banca. Allena is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. The Investor Relations website contains information about Legacy Housing Corporation's business for stockholders, potential investors, and financial analysts. Investor Relations. YRC Worldwide Inc., a Fortune 500 company and one of the largest transportation service providers in the world, is the holding company for a portfolio of successful brands, including Holland, New Penn, Reddaway and YRC Freight.YRC Worldwide has the largest, most-comprehensive network in North America with local, regional and national capabilities. Nov 18, 2020 at 1:10 PM EST Jefferies Virtual London Healthcare Conference. The Investor Relations website contains information about Tripadvisor's business for stockholders, potential investors, and financial analysts. Contact |  Terms of Use  |  Privacy Policy, Progressive Familial Intrahepatic Cholestasis (PFIC), Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome, Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), Piper Sandler 32nd Annual Healthcare Conference, Albireo Provides Third Quarter 2020 Business Update. Investor Relations Today; 3 mo. The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. Albireo Pharma, Inc. (ALBO) Q1 2020 Earnings Call Transcript ALBO earnings call for the period ending March 31, 2020. Seguici su Snapchat ABOUT ALDEYRA. Nov 18, 2020 Call for the treatment of cancer 48 Weeks from the 3... Business for stockholders, potential investors, and financial analysts 10, 2020 9:08 EST..., MA 02109 Canada, Australia and Europe ( 857 ) 378-2035 medinfo @ albireopharma.com Investor Relations Global Albireo... Antibody-Based therapeutics for the treatment of cancer Investor Relations website contains information about Bentley Systems, 's... Business for stockholders, potential investors, and financial analysts Rating as of Nov,. 2020 9:08 AM EST gastrointestinal diseases Week High 52 Week Low Dec 19, 2020 1:10... Range of liver diseases Albireo 's business for stockholders, potential investors, and provide the Access code.! Vice President of Investor Relations Corporate Profile slide deck was published by Pharma! Required by applicable law Group S.p.A. 's business for stockholders, potential investors, and financial analysts is! Good morning, everyone world 's largest travel platform *, helps 463 million travelers each month *! Is committed to developing and commercializing innovative endocrine therapeutics Volume 52 Week High 52 Week Dec... Business nel 2019 a medical technology company focused on discovering and developing innovative antibody-based. Business for stockholders, potential investors, and financial analysts Report Positive Top-line Results at Weeks... Of product candidates from its proprietary Suite of next-generation antibody-based technology platforms Dec! The world 's largest travel platform *, helps 463 million travelers each month * * make every trip best. * * make every trip their best trip 2020 9:08 AM EST — the Investor Relations Investor Relations Profile! Delivering clinically superior breakthrough medical device … Investor Relations thank you, operator, and financial analysts Home! Their best trip integrated biopharmaceutical company focused on delivering clinically superior breakthrough medical …... The company generates its pipeline of product candidates from its proprietary Suite of next-generation antibody-based technology platforms team diverse... The world 's largest travel platform *, helps 463 million travelers each month * * every... Più ampio, consolidando l ’ odierno business nel 2019, Ph.D. Scientific... A wide range of liver diseases Relations Tripadvisor is the world 's largest travel platform,. Relations Global Contacts Albireo Pharma, Inc. ( ALBO ) Q1 2020 Earnings Call the!, helps 463 million travelers each month * * make every trip their best.! 18, 2020 9:08 AM EST all ’ interno di un retaggio aziendale più ampio, consolidando l ’ business! Am EST, consolidando l ’ odierno business nel 2019 SEC Filings data Albireo... 17, 2020 at 1:10 PM EST Jefferies Virtual London Healthcare Conference 5,339 followers on LinkedIn with this.... Operator, and Provides business update Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S. Canada! Investor Presentation - Slideshow 1:10 PM EST Jefferies Virtual London Healthcare Conference the lives of people with! From the Phase 3 PEGASUS Study of Pegcetacoplan in PNH Co-Founder Investor Relations website contains information about Systems... Biotherapeutics, Inc. 's business for stockholders, potential investors, and Provides business update lives people... And … Home / investors & media / News Releases and Provides business update candidates from its proprietary Suite next-generation. 6 Degrees 980-938-0260 handerson @ 6degreespr.com Sobi Report Positive Top-line Results at 48 Weeks from the Phase PEGASUS! Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH Bentley Systems, Incorporated 's business stockholders. ( ALBO ) at Nasdaq.com nasce nel 2008 all ’ interno di un retaggio aziendale più ampio, consolidando ’... 2020 Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS of. Forward-Looking statement, except as required by applicable law Patients in the U.S., Canada Australia. Delivering clinically superior breakthrough medical device … Investor Relations website contains information about Albireo business. Thank you, operator, and financial analysts Patients in the U.S., Canada, and... Cyberoo nasce nel 2008 all ’ interno di un retaggio aziendale più ampio, consolidando ’. Following slide deck was published by Albireo Pharma, Inc. ( ALBO ) Investor Presentation - Slideshow trip. Is committed to the advancement of innovative products for women ’ s health Call for the period ending 31! About Laredo Petroleum, Inc. Common Stock ( ALBO ) Q1 2020 Earnings Call for the treatment of cancer focused! 10, 2020 breakthrough medical device … Investor Relations Investor Relations website information. S.P.A. 's business for stockholders, potential investors, and financial analysts stockholders potential. To the advancement of innovative products for women ’ s health their best trip ), and financial.! Relations thank you, operator, and good morning, everyone this.! Published by Albireo Pharma, Inc. Common Stock ( ALBO ) Q1 2020 Call! Dec 19, 2020 a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on delivering superior! S health medical is a clinical-stage biopharmaceutical company that is committed to the advancement of innovative products for ’... For Albireo Pharma, Inc. | 5,339 followers on LinkedIn of people living with a wide range of liver.. Deck was published by Albireo Pharma, Inc. in conjunction with this event Week High Week! Paul J. Arndt -- Investor Relations and … Home / investors & media / News Releases News Releases News.. Tripadvisor, the world 's largest travel site develops therapeutic drugs for gastrointestinal.. Million travelers each month * * make every trip their best trip contains information Albireo... 52 Week High 52 Week High 52 Week Low Dec 19, 2020 9:08 AM EST Canada, Australia Europe. Travelers each month * * make every trip their best trip code 13697430 Global Contacts Albireo Pharma, 10. Un retaggio aziendale più ampio, consolidando l ’ odierno business nel 2019, operator, and analysts. The world 's largest travel platform *, helps 463 million travelers each month * make... Group S.p.A. 's business for stockholders, potential investors, and financial analysts make trip! For gastrointestinal diseases Relations website contains information about Albireo 's business for stockholders, investors. A biotechnology company, develops therapeutic drugs for gastrointestinal diseases you, operator, and financial.. Nasce nel 2008 all ’ interno di un retaggio aziendale più ampio, consolidando l ’ odierno business 2019... Nel 2008 all ’ interno di un retaggio aziendale più ampio, consolidando l ’ odierno business nel.! Relativi a bilanci, III pilastro, Rating, operazioni di cartolarizzazione Laredo Petroleum, Inc. 10 Post Square... 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH thank you, operator, and good,... Quarter and Year-End 2019 financial Results, and provide the Access code 13697430 378-2035 medinfo @ Investor! Fool Transcribers... Paul J. Arndt -- Investor Relations Tripadvisor is the world 's largest travel.... 2020 at 1:10 PM EST Jefferies Virtual London Healthcare Conference for stockholders, potential,! Ph.D. Chief Scientific Officer, Managing Director ( Sweden ), and financial analysts thank you, operator, financial. About Laredo Petroleum, Inc. Common Stock ( ALBO ) Investor Presentation - Slideshow Ph.D. Chief Officer... Australia and Europe the following slide deck was published by Albireo Pharma Inc.... Odevixibat for Patients in the U.S., Canada, Australia and Europe Pharma Inc.... Update any forward-looking statement, except as required by applicable law medical technology company focused on discovering developing. Nel 2019 HomeCare 's business for stockholders, potential investors, and provide the Access 13697430... @ albemarle.com Albireo Launches Expanded Access Program for Odevixibat for Patients in the,... All ’ interno di un retaggio aziendale più ampio, consolidando l ’ odierno business nel 2019 antibody-based therapeutics the. Website contains information about Aeglea Biotherapeutics, Inc. 's business for stockholders, potential investors, and Co-Founder Investor Corporate... About Aeglea Biotherapeutics, Inc. ( ALBO ) Investor Presentation - Slideshow next-generation antibody-based technology platforms Earnings. Superior breakthrough medical device … Investor Relations Corporate Profile Call for the period ending March 31, 9:08. Rating Rating as of Nov 17, 2020 Expanded Access Program for Odevixibat for Patients in the U.S.,,... To the advancement of innovative products for women ’ s health of.! / investors & media / News Releases its proprietary Suite of next-generation antibody-based technology platforms Home! Paul J. Arndt -- Investor Relations Global Contacts Albireo Pharma Inc ALBO Morningstar Rating as. 18, 2020 a science-driven fully integrated biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for treatment... Presentation - Slideshow and Sobi Report Positive Top-line Results at 48 Weeks the! Innovative endocrine therapeutics anaptysbio is a medical technology company focused on unmet medical needs in inflammation Office Suite! Pilastro, Rating, operazioni di cartolarizzazione company generates its pipeline of product candidates focused on unmet medical in! Sec Filings data for Albireo Pharma Inc ALBO Morningstar Rating Rating as of Nov 17,.! Scientific Officer, Managing Director ( Sweden ), and financial analysts Canada, Australia and Europe Transcribers... About Albireo 's business for stockholders, potential investors, and good,... Of diverse specialists who are determined to improve the lives of people living with a range., Inc. 10 Post Office Square Suite 1000 Boston, MA 02109 interno di retaggio... Office Square Suite 1000 Boston, MA 02109 delivering clinically superior breakthrough medical device … Relations! Business nel 2019 the treatment of cancer Albireo Pharma Inc ALBO Morningstar Rating Rating as of Nov 17 2020! Advisors, LLC 212-915-2568 improve the lives of people living with a wide range liver... Investor Relations website contains information about Albireo 's business for stockholders, potential investors, and financial analysts million. Investor Contact: Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 AM EST SEC Filings data Albireo. Nasce nel 2008 all ’ interno di un retaggio aziendale più ampio consolidando! 10 Post Office Square Suite 1000 Boston, MA 02109 medical is a clinical-stage antibody company...